- Research
- Open access
- Published:
A parallel bioreactor strategy to rapidly determine growth-coupling relationships for bioproduction: a mevalonate case study
Biotechnology for Biofuels and Bioproducts volume 18, Article number: 6 (2025)
Abstract
Background
The climate crisis and depleting fossil fuel reserves have led to a drive for ‘green’ alternatives to the way we manufacture chemicals, and the formation of a bioeconomy that reduces our reliance on petrochemical-based feedstocks. Advances in Synthetic biology have provided the opportunity to engineer micro-organisms to produce compounds from renewable feedstocks, which could play a role in replacing traditional, petrochemical based, manufacturing routes. However, there are few examples of bio-manufactured products achieving commercialisation. This may be partially due to a disparity between academic and industrial focus, and a greater emphasis needs to be placed on economic feasibility at an earlier stage. Terpenoids are a class of compounds with diverse use across fuel, materials and pharmaceutical industries and can be manufactured biologically from the key intermediate mevalonate.
Results
Here, we report on a method of utilising parallel bioreactors to rapidly map the growth-coupling relationship between the specific product formation rate, specific substrate utilisation rate and specific growth rate. Using mevalonate as an example product, a maximum product yield coefficient of 0.18 gp/gs was achieved at a growth rate (\(\mu\)) of 0.34 h−1. However, this process also led to the formation of the toxic byproduct acetate, which can slow growth and cause problems during downstream processing. By using gene editing to knock out the ackA-pta operon and poxB from E. coli BW25113, we were able to achieve the same optimum production rate, without the formation of acetate.
Conclusions
We demonstrated the power of using parallel bioreactors to assess productivity and the growth-coupling relationship between growth rate and product yield coefficient of mevalonate production. Using genetic engineering, our resultant strain demonstrated rapid mevalonate formation without the unwanted byproduct acetate. Mevalonate production is quantified and reported in industrially relevant units, including key parameters like conversion efficiency that are often omitted in early-stage publications reporting only titre in g/L.
Background
Depleting fossil fuels reserves and climate change concerns have pushed synthetic biology to demonstrate production of a vast array of bioderived commodity and high-value compounds [1,2,3,4]. However, despite being able to bio-produce many compounds with the potential to replace fossil fuel derived counterparts, few of these production methods have reached commercialisation [5].
Common barriers to the commercialisation of bioprocesses are financial, regulatory and the availability of appropriate facilities [6]. In academia, the financial viability of a process is often considered secondary to the advancement of scientific knowledge. However, if more processes are to reach commercialisation, whether through the growth of spinout companies or investment by larger established industrial partners, the financial viability of a process needs to be taken into consideration earlier in the development cycle.
The commercial viability of a bioprocess can be studied through the use of techno economic analysis (TEA) [7], where a well-founded TEA can help to encourage and de-risk potential investment. These analyses not only look at reported titres but consider other factors such as the capital cost of building the fermentation plant (CAP-EX), ongoing operating costs (OP-EX), such as energy and raw substrate requirements, and down-stream processing [7]. All are factors that are not typically considered at the academic discovery stage.
Mevalonate is a 5-carbon carboxylic acid with uses in the cosmetics industry, but mainly serves as a precursor for terpene synthesis with broad application in pharmaceutical, flavour/fragrance and fuel industries [8]. Mevalonate is produced from central metabolism by the mevalonate pathway in three enzymatic steps from acetyl-CoA (Fig. 1). Terpenes are usually found in nature as plant secondary metabolites [9]. However, when they are produced by heterologous expression of the enzymatic pathway during growth phase, they can be considered growth-coupled, primary metabolites, due to the competition for acetyl-CoA flux. The highest reported production titres of mevalonate by E. coli are 111.3 g/L during a 120 h, fed-batch fermentation [10] or 47 g/L in a 50 h fed-batch fermentation [11]. However, we propose that titres reported in g/L lack key information relating to time and substrate requirements, so instead study productivity via specific product formation rate (qp) in gp/gx/h. We also recognise the impact specific growth rate (\(\mu\)) has on qp and product yield coefficient (Yp/s), so endeavour to study a full ‘growth-coupling relationship’.
Reaction scheme of E. coli central metabolism, overflow metabolism, stationary phase acetate production and mevalonate production. AcCoA = acetyl-CoA, HMG-CoA = 3-hydroxy-3-methylglutaryl-CoA, MVA = mevalonate, AACT = acetoacetyl-CoA thiolase, HMGR = 3-hydroxy-3-methylglutarate reductase, HMGS = 3-hydroxy-3-methylglutarate synthase, Pta = phosphate acetyltransferase, AckA = acetate kinase, PoxB = pyruvate oxidase, TCA = tricarboxylic acid, PDH = pyruvate dehydrogenase complex
Parallel bioreactors, such as the Sartorius AMBR250 system, allow multiple fermentations to be carried out simultaneously, decreasing the time required to generate data. Growth-coupling relationships are strain and condition specific, and therefore will vary for every bioprocess. It is possible to use parallel bioreactor systems to rapidly estimate the landscape of the growth-coupling relationship within a single experimental run, using calculated fed-batch feeds to achieve pseudo steady-state growth conditions, without the need for long and challenging chemostat experiments or sequential fed-batch fermentations. Parallelisation decreases the time, and therefore cost, associated with studying these relationships and could be readily implemented during academic studies. Making these data available during low technology readiness level research [12], could help navigate the landscape of technoeconomic analysis, in a cost-effective manner, when compared to titre alone which provides a single datapoint. In turn, this could help commercialisation of the vast array of compounds produced by synthetic biology.
During fermentations with excess glucose or high growth rates, E. coli produces acetate through so called ‘overflow’ metabolism (Fig. 1) [13]. The purpose and effects of overflow metabolism are debated, but it is thought that production of acetate may help restore cofactor availability, maintain redox balance and regenerate CoA pool from acetyl-CoA accumulation. However, acetate accumulation is toxic to the cell, affecting growth and, therefore, is undesirable during a fermentation process [14]. In addition, removal of dilute acetate from aqueous fermentation broth during downstream processing (DSP) is challenging, especially if the product of interest is an organic acid, such as mevalonate [15,16,17]. Therefore, we knocked out the main acetate producing pathways in E. coli, poxB and ackA/pta operon (Fig. 1), and showed that we can maintain the same production rates, without the build-up of a toxic and hard to separate byproduct.
Results
Steady-state, fed-batch mevalonate production
An initial batch fermentation was used to calculate the biomass yield coefficient (YX/S) and maximum growth rate (\(\mu\)max) of E. coli BW_MvaES (Fig. 2). The strain was induced to replicate the growth kinetics of the producing strain. In the batch medium, all growth nutrients are in excess, and therefore, the growth rate during the batch phase can be assumed to be \(\mu\)max.
Calculation of Yx/s and \(\mu\)max of BW_MvaES (n = 2). A) Plot of biomass against glucose with a gradient equal to YX/S (0.5 gx/gs, root mean squared error (RMSE) = 0.0053, correlation coefficient (R2) = 0.994) (blue = bioreactor 1, orange = bioreactor 2). B) Natural logarithm of biomass against time since inoculation, where gradient gives an assumed \(\mu\)max (0.47 h−1, RMSE = 0.016, R2 = 0.999)
These values were then used to calculate feeding rates (Eq. 1) to give the desired, fixed growth rates (\(\mu\)set). The feeding rates (Eq. 1) assume a constant volume, and therefore the measured rates are only true when the volume of feed added is significantly lower than the initial volume. This means that only initial rates remain constant, and as feed volume increases over time, \(\mu\) tends to decrease. However, whilst the amount of feed added remains significantly smaller than the initial culture volume, the cells are generally considered to be in steady state [18]. Steady state, \(\mu\)set values of 0.45, 0.375, 0.3, 0.225, 0.15 and 0.075 were selected to give broad coverage over biologically relevant growth rates:
Equation 1 Calculating feeding rates (Ft) to give desired \(\mu\)set. ms = maintenance value (0.06 gs/gx/h [19]), x0 = initial biomass concentration (g/L), v0 = initial culture volume (l), \(\omega_{in}\) = concentration of rate limiting substrate in feed, t = time (h).
Initially, in all fed-batch reactions, steady-state conditions with constant growth rates were achieved (Fig. 3 A). The linearity of the plots indicates steady-state conditions and variation of qp with growth rate, confirms that production is growth coupled. For the lower growth rates, the specific growth rate was equal to \(\mu\)set. However, for \(\mu\)set 0.45 h−1 and 0.375 h−1, the specific growth rates were slightly lower than desired. This was because the glucose uptake rate was too low resulting in accumulation of glucose in the medium (Fig. 3 D). As expected, the highest specific substrate consumption rates (qs) were by cultures with the highest \(\mu\)set (Fig. 3 C). The highest \(\mu\)set also gave rise to the highest specific product formation rates (qp) of mevalonate, up to 0.14 gp/gx/h (Fig. 3 B). However, during growth at the highest \(\mu\)set values (0.45, 0.375 and 0.3 h−1), acetate was produced and accumulated in the culture medium (Fig. 3 D).
Mevalonate production by BW_MvaES, during six parallel fed-batch fermentations with defined \(\mu\)set values. Values normalised to t = 0, for the beginning of steady-state conditions after batch phase, once feed has begun. A Specific growth rate of fed-batch reactions. B Specific product formation rate (qp) of fed-batch reactions. C Specific substrate consumption rate (qs) of fed-batch reactions. D amount of glucose and acetate present in the culture medium (based on HPLC sample analysis) (solid lines acetate, dotted lines glucose). E Table containing the values, RMSE and R2 of \(\mu\), qp and qs for each \(\mu\)set, obtained from panels A-C, and titre after 24 h of feeding. Blue circles: \(\mu\)set = 0.45 h−1, orange squares: \(\mu\)set = 0.375 h−1, grey diamonds: \(\mu\)set = 0.3 h−1, yellow triangles: \(\mu\)set = 0.225 h−1, light blue squares: \(\mu\)set = 0.15 h−1, green circles: \(\mu\)set = 0.075 h−1
Growth-coupling of mevalonate production
By analysing the relationship between qs, qp and \(\mu\) (obtained in Fig. 3), it was possible to determine the growth rate at which the largest proportion of substrate was diverted to product, as demonstrated by a high product yield coefficient (YP/s) (Fig. 4). In the case of mevalonate production by BW_MvaES, high growth rates gave the highest YP/S (0.18 gP/gS at 0.34 h−1), whereas a growth rate of 0.07 h−1 produced threefold less product per g substrate (0.06 gP/gS)
Using CRISPR to engineer acetate-free, mevalonate-producing strains
CRISPR–cas12a was used to knockout the acetate production pathways native to E. coli [20]. The ackA-pta operon is responsible for acetate production during exponential growth when glucose uptake rates are high. During stationary phase metabolism, poxB is responsible for most acetate produced (Fig. 1) [13]. The general effectiveness of reducing acetate formation by knocking out these pathways was assessed by growth on Luria–Bertani (LB) supplemented with 20 g/L glucose to induce acetate formation. Under these conditions, knocking out a single pathway did not remove acetate production, presumably due to compensatory metabolism allowing the cells to utilise an alternative pathway (Fig. 5). However, knocking out both ackA-pta and poxB significantly reduced acetate production by E. coli (Student’s t-test: p < 0.05).
Acetate-free fed-batch, mevalonate production
The ΔackApta ΔpoxB double knockout (KO) KO_MvaES was assessed for its ability to produce mevalonate. Batch cultures of the KO strain were used to calculate YX/S and \(\mu\)max (Fig. 6). These were then used to determine Ft (Eq. 1). \(\mu\)set values of 0.4, 0.35, 0.3, 0.25, 0.2 and 0.15 h−1 were selected so that gs/gx/h could be measured across a range of relevant growth rates.
Using feeding rates calculated from Fig. 6, all six fed-batch fermentations achieved constant specific growth rates (Fig. 7 A). Similarly to BW_MvaES, the highest two \(\mu\)set values led to slightly lower than expected \(\mu\), due to the accumulation of glucose in the culture medium. However, unlike BW_MvaES, acetate was not detectable during any of the fermentations. Again, the highest \(\mu\)set led to the highest qs and qp, and vice versa (Fig. 7 B and C). The highest qp value was 0.13 gp/gx/h at a \(\mu\)set of 0.4 or 0.35 h−1.
Mevalonate production by KO_MvaES, during six parallel fed-batch fermentations with defined \(\mu\)set values. Values normalised to t = 0, for the beginning of steady-state conditions after batch phase, once feed has begun. A Specific growth rate of fed-batch reactions. B Specific product formation rate (qp) of fed-batch reactions. C Specific substrate consumption rate (qs) of fed-batch reactions. D Amount of glucose present in the culture medium. E Table containing the values, root mean squared error (RMSE) and correlation coefficient (R2) of \(\mu\), qp and qs for each \(\mu\)set, obtained from panels A-C, and titre after 24 h of feeding. Blue circles: \(\mu\)set = 0.4 h−1, orange squares: \(\mu\)set = 0.35 h−1, grey diamonds: \(\mu\)set = 0.3 h−1, yellow triangles: \(\mu\)set = 0.25 h−1, light blue squares: \(\mu\)set = 0.2 h−1, green circles: \(\mu\)set = 0.15 h−1
Acetate-free growth coupling of mevalonate production
The highest YP/S for KO_MvaES was 0.18 gp/gs, achieved at a \(\mu\) of 0.34 h−1 (Fig. 8). At growth rates lower than this, YP/S decreases, with an almost a fivefold lower qs to qp ratio (0.039 gp/gs), at a \(\mu\) of 0.15 h−1.
Discussion
Reporting product titres in g/L is standard practice in academia [10, 11, 21, 22]. However, these values provide little relevant context when considering scaling up a process, where time and amount of substrate are both important factors in considering scaling costs. This is because whilst Cap-EX of a pilot or industrial plant are important, the ongoing Op-Ex, such as substrate provision, are far more important as they are paid for over the lifetime of the plant [23]. The only way to recover these costs is by production of the compound of interest, therefore the time required, and amount of product made are vital. Here, we studied the production of mevalonate in terms of rates, in the form qp and qs. The units, g/gx/h, are related to product/substrate, biomass, and time. These may inform a more detailed TEA, based on the timescale of a production run and feedstock requirements rather than just endpoint titre.
Products made during fermentation, directly from metabolic substrates, are often considered to be ‘growth coupled’ [24]. Growth coupling results from cells having a ‘choice’ over how to utilise each unit of substrate. The substrate may be used by the cell to make a compound of interest, generate biomass or contribute towards cellular maintenance (ms, Eq. 1), such as pumping ions to maintain intracellular pH, producing side products or regeneration of proteins. For calculating Ft (Eq. 1), a literature value of 0.06 gs/gx/h was used. However, by plotting qs against \(\mu\) for BW25113_MvaES (Additional File 1: Fig. 1), the observed ms of 0.053 gs/gx/h can be obtained from the intercept. From this plot it is also possible to determine the Yx/s, through the inverse of the gradient (0.47 gx/gs, RMSE = 0.009). This value is significantly lower than the estimate of 0.5 gx/gs (Fig. 2 A) (Student’s t-test p = 0.0102). The Yx/s of KO_MvaES is significantly lower than that of BW25113_MvaES (Additional file 1: Fig. 2) (0.38 gx/gs, RMSE = 0.012) (Student’s t-test p < 0.05), indicating the knockouts are affecting the conversion of substrate to biomass.
Equation 1 was successful in generating steady-state growth conditions, as shown by the high R2 values of the linear growth rate plots (Figs. 3 A and 7 A). Equally, the linearity and growth rate dependence of qp, confirms that mevalonate production was growth coupled. As steady-state conditions are achieved, RMSE can give an estimate of experimental error, without the need for multiple runs at each growth rate. As the goal is to rapidly estimate important parameters at a low level of technology readiness, reducing the number of experimental runs is important in increasing speed and reducing costs, to make the process widely applicable. However, repeating the fermentation of BW_MvaES at a \(\mu\)set of 0.3 h−1 (Additional file 1: Fig. 3), shows no significant difference in the values of qs (Student’s t-test p = 0.9), qp (Student’s t-test p = 0.95) or YP/S (Student’s t-test p = 0.72), demonstrating the reproducibility of the process.
The growth-coupling relationship is usually growth rate dependent, where cellular resources and cell metabolism at different growth rates may affect the partitioning of resources and therefore the proportion of substrate diverted to product. The relationship is strain and condition specific, and changes through genetic engineering or modification of growth conditions can affect the outcome.
Here, we studied growth-coupling relationships in the form of YP/S at different growth rates (Figs. 4 and 8), for BW_MvaES and KO_MvaES under defined growth conditions. The growth-coupling relationship for both strains aligned with previous observations [25] that higher growth rates provide increased acetyl-CoA availability and therefore lead to increased mevalonate production, as shown by the significant decrease in YP/S between \(\mu\) of 0.33 h−1 and \(\mu\) bellow 0.3 h−1 (Student’s t-test p < 0.05).
YP/S indicates the amount of product formed per g substrate. Calculating this simple measure could already inform that a process is unlikely to be economically viable if substrate costs exceed the expected revenue from product sold. In the strains assessed here, both achieved the same maximum YP/S of 0.18 gp/gs, indicating that both strains had the same maximum efficiency. If these strains had been studied in a typical manner, looking only at titre, it may not have been apparent that the knockouts did not affect efficiency. To achieve maximum efficiency, both strains must be grown at a rate of approximately 0.34 h−1. Knowledge of this can inform process design to ensure substrate feeding maintains growth rates favourable for maximum yield. In addition, both strains had the same maximum productivity, with no significant difference in qp value (Student’s t-test p > 0.05), indicating that the rate of product formation was also the same. Knockouts did not significantly affect qs at either \(\mu\)set 0.3 h−1 or 0.15 h−1 (Student’s t-test p > 0.05).
The landscape of the growth-coupling relationship gives an indication of the robustness of the strain to changes in growth rate. This is an important consideration in scale-up, where mass transfer and mixing effects may lead to a heterogeneous population within the reactor, with not all cells growing under optimal conditions for product formation [26]. Comparing BW_MvaES and KO_MvaES, as \(\mu\) decreases from the optimum the KO_MvaES was more adversely affected with lower YP/S values (0.04 gp/gs versus 0.09 gp/gs at a \(\mu\) of 0.15 h−1). The low YP/S values at low growth rates represent a 3- to 5-fold higher minimum selling price for product, based on substrate cost per product, when compared to the same strain achieving its maximum efficiency. This would not have been identified by studying the endpoint titre for BW_MvaES and KO_MvaES.
Whilst both strains achieved the same maximum productivity, KO_MvaES achieved this without the formation of acetate as a byproduct. Acetate formation is undesirable as it can inhibit growth from around 5 g/L, which could prevent the desired growth rate being achieved at higher cell densities [27]. Additionally, the OP-Ex of DSP are one of the most significant factors affecting the commercialisation of fermentation based routes to organic acids because separating dilute mixed products is challenging [17]. Removal of acetate as a significant byproduct can help reduce the costs associated with DSP [16]. In industry, one common approach to reducing acetate formation is to reduce growth rate [28]. However, by reducing growth rate the productivity of BW_MvaES would be reduced, as can be seen by the lower YP/S and qp values (Figs. 3, 4).
Typically, productivities are studied during steady-state growth in a chemostat [29]. However, the time, workload and practicality of studying multiple growth rates, makes rapidly determining a growth-coupling relationship challenging. More recently, accelerostat cultivation has been used, where increasing dilution rates are used to generate quasi-steady state conditions, until washout occurs [30]. However, this requires the use of specialist reactors with the ability to maintain a constant culture volume. Additionally, these systems can only maintain steady-state conditions for a short period of time and are therefore very different to how an industrial process would be carried out.
Fed-batch is a common mode of industrial fermentation. Studying steady-state conditions during fed-batch, allowed parallel bioreactors (ambr250) to be utilised, and the growth-coupling relationship to be calculated in a single experimental run. By parallelising the fermentations, growth-coupling relationships were calculated more rapidly than would have been possible during a chemostat study or by carrying out multiple fed-batch runs in a single, larger-scale fermenter. Parallelisation allows characterisation to be accelerated in a standardised manner, which is of interest in both the academic setting, and the SME (small and medium-sized enterprise) world, where time is money, and currently much de-risking of scale-up is carried out. Whilst demonstrated for mevalonate production, this process could readily be applied to many bioprocesses irrespective of product or production strain, for which growth-coupling relationships would likely differ and could lead to more efficient and commercially viable processes.
As studies here assumed a constant volume (Eq. 1), the rates are only true if the volume of feed added is significantly lower than the initial volume and therefore, only initial rates remain constant, and as feed volume increases, \(\mu\) tends to decrease.
The purpose of this study was not to achieve maximum titres, but instead strain characterisation which can aid understanding and future process development. Since titre is intrinsically linked to production time, maximum titres would be achieved by maintaining a growth rate which gives the highest product yield coefficient, until high cell densities prevent further growth. This could be achieved by using a modified feeding equation, which adds a dilution factor to account for changes in volume from feed addition (Additional file 1: Eq. 1). However, the maximum oxygen transfer rate of our system is too low to support the high oxygen uptake rates required by the high growth rates and high cell densities needed to demonstrate this further.
Another metric commonly used to assess bioprocesses is overall volumetric productivity (gp/L/h). This is a characteristic of the process. It considers the reaction time and maximum titre and is independent of scale. Under the current feed rates, mevalonate concentrations of over 25 g/L were reached in less than 24 h (1.04 g/L/h) (Figs. 3 and 7). However, these titres were reached after the initial steady-state conditions (5 h for \(\mu\)set = 0.4). Therefore, for much of the fermentation, lower growth rates with less desirable YP/S were present, reducing endpoint titre. Despite this, observed volumetric productivities were comparable to other studies of mevalonate production from glucose, where 47 g/L was reached in 50 h (0.94 g/L/h) [11], without the co-accumulation of acetate. Additionally, these titres were achieved by process design, with limited costly and time-consuming strain engineering, in just two rounds of fermentation (preliminary calculation of Yx/s, \(\mu\)max and x0, then simultaneous quantification of qs and qp across a range of \(\mu\)set), showing the importance of process design and demonstrating the ability of the process to rapidly achieve competitive titres.
Conclusions
Here we report the use of parallel bioreactors to rapidly determine growth-coupling relationships of mevalonate production. By studying these in terms of productivity, we accessed industrially relevant insights, which would not be possible using traditional, titre-based reporting. This led to the development of a process capable of producing mevalonate at high rates without undesirable acetate formation and limited strain engineering. The process we developed could be applied to many fermentation products, to help to rapidly improve the efficiency of fermentation and to inform further process design and commercial feasibility studies.
Materials and methods
Construction of mevalonate-producing strain
mvaE and mvaS from Enterococcus faecalis were cloned into pBbS1k [31]. The resultant plasmid, pBbs1k_MvaES (Additional file 1: Fig. 4), was used for mevalonate production. This was transformed into electrocompetent E. coli BW25113, giving strain BW_MvaES.
Parallel bioreactor fermentation
Fermentations were carried out in a Sartorius AMBR250 bioreactor system. Fermentations contained 150 mL of batch medium. Batch medium contained M9 salts (Sigma Aldrich), 4 g/L glucose, 2 mM MgSO4, 0.1 mM CaCl2, 50 \(\mu\)M kanamycin and trace elements (100 × 5 g/L EDTA.2Na.2H2O, 830 mg/L FeCl3.6H2O, 84 mg/L ZnCl2, 13 mg/L CuCl2.2H2O, 10 mg/L CoCl2.6H2O, 10 mg/L H3BO3, 1.6 mg/L MnCl2.4H2O). The temperature was maintained at 32 °C and the pH controlled at 7 via automatic addition of 15% NH4OH. Dissolved oxygen (DO) concentration was maintained at 30% by a stirring cascade, with a constant airflow of 1 v/v/min. Expression of mvaES was induced at approximately OD600 1 by the addition of 250 \(\mu\)M IPTG. Feeding began after DO spiked above 50%, indicating starvation had occurred. Feed solution contained 500 g/L glucose, M9 salts, 5 × trace elements, 5 mM MgSO4, 250 \(\mu\)M IPTG, 50 \(\mu\)M kanamycin.
Sample analysis
Quantification of glucose, mevalonate and acetate was carried out by HPLC. A REZEX ROA column was used, with an aqueous 5 mM H2SO4 mobile phase. The chromatography was run isocratically at 0.6 mL/min, at 55 °C for 30 min with RI detection. Analytical standards were used to generate curves for quantification (Additional file 1: Fig. 5).
Knocking out acetate production
Acetate producing genes were knocked out of E. coli BW25113 using CRISPR–Cas12a, as used by Jervis et al. (20). 500 bp homology arms upstream and downstream of poxB and the ackA_pta operon were synthesised as gblocks by IDT and used to construct pTarget_AckApta (Additional file 1: Fig. 6) and pTarget_poxB (Additional file 1: Fig. 7). The knockout strain was made electrocompetent and transformed with pBbS1k_MvaES, to give the production strain KO_MvaES.
Strain screening
Strains were screened in 250-mL flasks, containing 50 mL LB ± 20 g/L glucose. mvaES expression was induced at OD600 1 with 250 \(\mu\)M IPTG. Cultures were grown at 32 °C for 16 h in a 200 rpm shaking incubator.
Availability of data and materials
The genome sequence of E. coli BW25113 is available on GenBank (GCA _ GCA_016811895).
Abbreviations
- TEA:
-
Techno economic analysis
- CAP-EX:
-
Capital expenditure
- OP-EX:
-
Operating expenditure
- qp :
-
Specific product formation rate
- μ:
-
Specific growth rate
- qs :
-
Specific substrate consumption rate
- Yp/s :
-
Product yield coefficient
- AcCoA:
-
Acetyl-CoA
- HMG-CoA:
-
3-Hydroxy-3-methylglutaryl-CoA
- MVA:
-
Mevalonate
- AACT:
-
Acetoacetyl-CoA thiolase
- HMGR:
-
3-Hydroxy-3-methylglutarate reductase
- HMGS:
-
3-Hydroxy-3-methylglutarate synthase
- Pta:
-
Phosphate acetyltransferase
- AckA:
-
Acetate kinase
- PoxB:
-
Pyruvate oxidase
- TCA:
-
Tricarboxylic acid
- DSP:
-
Downstream processing
- KO:
-
Knockout
References
Hillson N, Caddick M, Cai Y, Carrasco JA, Chang MW, Curach NC, et al. Building a global alliance of biofoundries. Nat Commun. 2019;10(1):2040.
Casini A, Chang F-Y, Eluere R, King AM, Young EM, Dudley QM, et al. A pressure test to make 10 molecules in 90 days: external evaluation of methods to engineer biology. J Am Chem Soc. 2018;140(12):4302–16.
Carbonell P, Jervis AJ, Robinson CJ, Yan C, Dunstan M, Swainston N, et al. An automated design-build-test-learn pipeline for enhanced microbial production of fine chemicals. Communications Biology. 2018;1(1):66.
Miller DC, Athavale SV, Arnold FH. Combining chemistry and protein engineering for new-to-nature biocatalysis. Nat Synth. 2022;1(1):18–23.
Commission E. Building the future with nature: boosting biotechnology and biomanufacturing in the EU. 2024.
Department for Business EIS. Growing the bioeconomy: a national bioeconomy strategy to 2030 2018. https://www.gov.uk/government/publications/bioeconomy-strategy-2018-to-2030/growing-the-bioeconomy-a-national-bioeconomy-strategy-to-2030#business-environment.
Scown CD, Baral NR, Yang M, Vora N, Huntington T. Technoeconomic analysis for biofuels and bioproducts. Curr Opin Biotechnol. 2021;67:58–64.
Wang C-H, Hou J, Deng H-K, Wang L-J. Microbial production of mevalonate. J Biotechnol. 2023;370:1–11.
Ninkuu V, Zhang L, Yan J, Fu Z, Yang T, Zeng H. Biochemistry of terpenes and recent advances in plant protection. Int J Mol Sci. 2021;22(11):5710.
Zhu Y, Li Y, Xu Y, Zhang J, Ma L, Qi Q, et al. Development of bifunctional biosensors for sensing and dynamic control of glycolysis flux in metabolic engineering. Metab Eng. 2021;68:142–51.
Tabata K, Hashimoto S-I. Production of mevalonate by a metabolically-engineered Escherichia coli. Biotech Lett. 2004;26(19):1487–91.
Mankins JC. Technology readiness assessments: a retrospective. Acta Astronaut. 2009;65(9):1216–23.
Wolfe AJ. The acetate switch. Microbiol Mol Biol Rev. 2005;69(1):12–50.
Nakano K, Rischke M, Sato S, Märkl H. Influence of acetic acid on the growth of Escherichia coli K12 during high-cell-density cultivation in a dialysis reactor. Appl Microbiol Biotechnol. 1997;48(5):597–601.
Cheng K-K, Zhao X-B, Zeng J, Wu R-C, Xu Y-Z, Liu D-H, et al. Downstream processing of biotechnological produced succinic acid. Appl Microbiol Biotechnol. 2012;95(4):841–50.
Chen C, Zhang X, Liu C, Wu Y, Zheng G, Chen Y. Advances in downstream processes and applications of biological carboxylic acids derived from organic wastes. Biores Technol. 2022;346: 126609.
Li QZJX, Feng XJ, Wang JM, Sun C, Zhang HB, Xian M, Liu HZ. Recovery processes of organic acids from fermentation broths in the biomass-based industry. J Microbiol Biotechnol. 2016;26:1–8.
Stanbury PF, Whitaker A, Hall SJ. Microbial growth kinetics. In: Stanbury PF, Whitaker A, Hall SJ, editors. Principles of fermentation technology. 3rd ed. Oxford: Butterworth-Heinemann; 2017. p. 21–74.
Pirt SJ. The maintenance energy of bacteria in growing cultures. Proc R Soc Lond B. 1965;163(991):224–31.
Jervis AJ, Hanko EKR, Dunstan MS, Robinson CJ, Takano E, Scrutton NS. A plasmid toolset for CRISPR-mediated genome editing and CRISPRi gene regulation in Escherichia coli. Microb Biotechnol. 2021;14(3):1120–9.
Fink T, Stevović B, Verwaal R, Roubos JA, Gaber R, Benčina M, et al. Metabolic enzyme clustering by coiled coils improves the biosynthesis of resveratrol and mevalonate. AMB Express. 2020;10(1):97.
Wang J, Niyompanich S, Tai YS, Wang J, Bai W, Mahida P, et al. Engineering of a highly efficient Escherichia coli strain for mevalonate fermentation through chromosomal integration. Appl Environ Microbiol. 2016;82(24):7176–84.
van der Wielen LAM, Mussatto SI, van Breugel J. Bioprocess intensification: cases that (don’t) work. New Biotechnol. 2021;61:108–15.
Toya Y, Shimizu H. Coupling and uncoupling growth and product formation for producing chemicals. Curr Opin Biotechnol. 2024;87: 103133.
Masuda A, Toya Y, Shimizu H. Metabolic impact of nutrient starvation in mevalonate-producing Escherichia coli. Biores Technol. 2017;245:1634–40.
Noorman HJ, van Winden W, Heijnen JJ, van der Lans RGJM. Intensified fermentation processes and equipment. In: Górak A, Stankiewicz A, editors. Intensification of Biobased Processes: The Royal Society of Chemistry; 2018. p. 0.
Pinhal S, Ropers D, Geiselmann J, de Jong H. Acetate metabolism and the inhibition of bacterial growth by acetate. J Bacteriol. 2019. https://doiorg.publicaciones.saludcastillayleon.es/10.1128/JB.00147-19.
Eiteman MA, Altman E. Overcoming acetate in Escherichia coli recombinant protein fermentations. Trends Biotechnol. 2006;24(11):530–6.
Novick A, Szilard L. Description of the chemostat. Science. 1950;112(2920):715–6.
Nahku R, Valgepea K, Lahtvee P-J, Erm S, Abner K, Adamberg K, et al. Specific growth rate dependent transcriptome profiling of Escherichia coli K12 MG1655 in accelerostat cultures. J Biotechnol. 2010;145(1):60–5.
Lee TS, Krupa RA, Zhang F, Hajimorad M, Holtz WJ, Prasad N, et al. BglBrick vectors and datasheets: a synthetic biology platform for gene expression. J Biol Eng. 2011;5(1):12.
Acknowledgements
Thanks to Rosalind Le Feuvre and Matthew Faulkner for providing feedback on the manuscript.
Funding
This work was supported by the Future Biomanufacturing Research Hub (grant EP/S01778X/1), funded by the Engineering and Physical Sciences Research Council (EPSRC) and Biotechnology and Biological Sciences Research Council (BBSRC) as part of UK Research and Innovation.
Author information
Authors and Affiliations
Contributions
AB performed experimental work, data analysis, conceived the study and wrote drafts of the manuscript. JW knocked out the AckApta operon from E. coli BW25113, to form E. coli BW25113 \(\Delta\)ackApta and performed manuscript revisions. NSS performed manuscript revisions and secured funding.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
NS is a board member and co-founder of C3 Biotechnologies Ltd.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Banner, A., Webb, J. & Scrutton, N. A parallel bioreactor strategy to rapidly determine growth-coupling relationships for bioproduction: a mevalonate case study. Biotechnol. Biofuels Bioprod. 18, 6 (2025). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13068-024-02599-x
Received:
Accepted:
Published:
DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13068-024-02599-x